雅各臣科研制药(02633) - 2023 - 年度业绩

Annual Results Announcement for the Year Ended March 31, 2023 This report presents the annual results of Jacobson Pharma Corporation Limited for the financial year ended March 31, 2023, detailing financial performance, operational highlights, and future outlook Financial Highlights Jacobson Pharma Corporation Limited achieved significant growth in the financial year ended March 31, 2023, with substantial increases in revenue, operating profit, and profit for the year, alongside proposed final and in-specie special dividends FY2023 Financial Summary | Metric | FY2023 (HK$ million) | FY2022 (HK$ million) | Change (%) | | :----------- | :------------------- | :------------------- | :------- | | Revenue | 1,785.6 | 1,595.5 | +11.9% | | Operating Profit | 410.8 | 260.9 | +57.5% | | Profit for the Year | 283.2 | 187.7 | +50.9% | - The Board recommends a final dividend of 2.38 HK cents per ordinary share for the year ended March 31, 2023, totaling approximately HK$46.0 million (2022: 2.68 HK cents per share)[26] - Total dividends for the year ended March 31, 2023, amounted to 5.18 HK cents per ordinary share (2022: 3.88 HK cents per ordinary share)[26] - The Board also recommends a special dividend in the form of an in-specie distribution of 509 JBM shares for every 2,000 shares held by the Company's equity holders[26] Consolidated Financial Statements This section presents the consolidated financial statements, including the statement of profit or loss, financial position, and related notes, for the reporting period Consolidated Statement of Profit or Loss and Other Comprehensive Income For the year ended March 31, 2023, revenue grew by 11.9% to HK$1,785.6 million, gross profit by 20.4% to HK$747.2 million, operating profit by 57.5% to HK$410.8 million, and profit for the year by 50.9% to HK$283.2 million, driven by revaluation gains on financial assets Key Data from Consolidated Statement of Profit or Loss and Other Comprehensive Income | Metric | 2023 (HK$ thousand) | 2022 (HK$ thousand) | | :------------------- | :-------------- | :-------------- | | Revenue | 1,785,579 | 1,595,543 | | Cost of sales | (1,038,407) | (975,021) | | Gross profit | 747,172 | 620,522 | | Other net income | 91,658 | 40,499 | | Selling and distribution expenses | (196,723) | (184,087) | | Administrative and other operating expenses | (231,347) | (216,046) | | Operating Profit | 410,760 | 260,888 | | Finance costs | (67,445) | (25,687) | | Profit before tax | 339,755 | 231,433 | | Income tax expense | (56,546) | (43,728) | | Profit for the Year | 283,209 | 187,705 | | Other comprehensive income for the year | 108,057 | (25,742) | | Total comprehensive income for the year | 391,266 | 161,963 | | Profit attributable to owners of the Company | 251,044 | 177,666 | | Profit attributable to non-controlling interests | 32,165 | 10,039 | | Basic and diluted earnings per share (HK cents) | 13.13 | 9.27 | Consolidated Statement of Financial Position As of March 31, 2023, total assets were HK$4,724.1 million, a 20.2% increase year-on-year, with cash and cash equivalents surging by 116.5% to HK$1,036.4 million, while net assets grew by 10.1% to HK$3,256.5 million Key Data from Consolidated Statement of Financial Position | Metric | 2023 (HK$ thousand) | 2022 (HK$ thousand) | | :------------------- | :-------------- | :-------------- | | ASSETS | | | | Non-current assets | 3,623,086 | 3,577,295 | | Investment properties | 181,172 | 230,472 | | Property, plant and equipment | 1,502,148 | 1,503,773 | | Intangible assets | 1,320,075 | 1,303,177 | | Interests in associates | 51,821 | 53,929 | | Interests in joint ventures | 3,616 | 4,334 | | Other non-current assets | 39,693 | 58,688 | | Other financial assets | 514,330 | 412,766 | | Deferred tax assets | 10,231 | 10,156 | | Current assets | 1,757,413 | 1,178,245 | | Inventories | 368,003 | 314,557 | | Trade and other receivables | 351,360 | 380,546 | | Current tax recoverable | 1,632 | 4,489 | | Cash and cash equivalents | 1,036,418 | 478,653 | | LIABILITIES | | | | Current liabilities | 1,100,978 | 351,861 | | Trade and other payables and contract liabilities | 283,653 | 159,411 | | Non-current liabilities | 1,467,542 | 971,191 | | Bank loans | 1,234,153 | 729,472 | | Lease liabilities | 20,534 | 34,319 | | Deferred tax liabilities | 212,855 | 207,400 | | EQUITY | | | | Net assets | 3,256,522 | 2,957,965 | | Total equity attributable to owners of the Company | 2,736,689 | 2,491,316 | | Non-controlling interests | 519,833 | 466,649 | | Total equity | 3,256,522 | 2,957,965 | Notes to the Consolidated Financial Statements This section provides detailed notes and explanations supporting the consolidated financial statements, covering company information, accounting policies, and key financial items Company Information Jacobson Pharma Corporation Limited is an investment holding company incorporated in the Cayman Islands, primarily engaged in the development, production, marketing, and sale of generic drugs and branded healthcare products, with its shares listed on the Main Board on September 21, 2016 - Jacobson Pharma Corporation Limited is an exempted company incorporated in the Cayman Islands, primarily engaged in the development, production, marketing, and sale of generic drugs and branded healthcare products[15] - The Company's shares were listed on the Main Board on September 21, 2016[15] Basis of Preparation The consolidated financial statements are prepared in accordance with all applicable Hong Kong Financial Reporting Standards and the disclosure requirements of the Hong Kong Companies Ordinance, complying with the Listing Rules, and are presented on a historical cost basis, except for investment properties and financial assets measured at fair value - The consolidated financial statements are prepared in accordance with all applicable Hong Kong Financial Reporting Standards (including all applicable individual HKFRSs, HKASs, and Interpretations issued by the HKICPA) and the disclosure requirements of the Hong Kong Companies Ordinance[17] - These financial statements also comply with the applicable disclosure provisions of the Listing Rules[17] - The Group's consolidated financial statements are prepared on a historical cost basis, except for investment properties and investments measured at fair value through other comprehensive income and fair value through profit or loss, which are presented at fair value[38] Changes in Accounting Policies During this accounting